0001213900-19-012450.txt : 20190710
0001213900-19-012450.hdr.sgml : 20190710
20190710172139
ACCESSION NUMBER: 0001213900-19-012450
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190628
FILED AS OF DATE: 20190710
DATE AS OF CHANGE: 20190710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pearson Mark E.
CENTRAL INDEX KEY: 0001486558
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14778
FILM NUMBER: 19950009
MAIL ADDRESS:
STREET 1: 3031 TISCH WAY
STREET 2: SUITE 505
CITY: SAN JOSE
STATE: CA
ZIP: 95128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLIGENIX, INC.
CENTRAL INDEX KEY: 0000812796
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 411505029
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-538-8200
MAIL ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: DOR BIOPHARMA INC
DATE OF NAME CHANGE: 20020329
FORMER COMPANY:
FORMER CONFORMED NAME: ENDOREX CORP
DATE OF NAME CHANGE: 19960916
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0306
4
2019-06-28
0
0000812796
SOLIGENIX, INC.
SNGX
0001486558
Pearson Mark E.
29 EMMONS DRIVE, SUITE B-10
PRINCETON
NJ
08540
1
0
1
0
Common Stock
2019-06-28
4
A
0
78338
0.71
A
78338
I
See footnote
Common Stock
2500000
D
These securities were issued in lieu of cash compensation payable for services rendered, with the number of shares issued being calculated based upon the closing price of $0.71 on June 28, 2019. The transaction is exempt under Rule 16b-3 of the Securities Exchange Act of 1934.
These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose.
/s/ Mark E. Pearson
2019-07-10